ClinicalTrials.gg
RecruitingNCT07293923Updated Jul 16, 2026

Magenta Elevate™ Clinical Feasibility Study in Cardiogenic Shock

An interventional study of Elevate™ System in Cardiogenic Shock, Heart Failure and Acute Myocardial Infarction (AMI), sponsored by Magenta Medical Ltd.. Recruiting at 8 sites in 2 countries. Open to participants aged 40 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Magenta Medical Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
40 Years to 89 Years
Sex
All
01

Study summary

The Elevate™ CS Clinical Feasibility Study is designed to evaluate the initial safety, effectiveness, and device performance of the Magenta Elevate™ System in patients with cardiogenic shock due to isolated or predominant left ventricular failure.

Read the detailed description

The Elevate™ CS Clinical Feasibility Study is planned as a prospective, single-arm, interventional study.

02

Conditions studied

  • Cardiogenic Shock
  • Heart Failure
  • Acute Myocardial Infarction (AMI)
03

In context

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

This study's planned enrollment of 10 is below the median of 80 across 133 interventional studies indexed under Shock, Cardiogenic.

Browse Shock, Cardiogenic studies →

Lead sponsor

Magenta Medical Ltd. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cardiogenic shock of less than 24 hours duration.
  • \< 45% and > 15%, as determined by echocardiography on the day of inclusion.
  • No more than mild right ventricular dysfunction, as determined by echocardiography on the day of inclusion.
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Other causes of shock: hypovolemia, sepsis (any active systemic infection including acute myocarditis), pulmonary embolism or anaphylaxis.
  • Patient with oxygen saturation \< 90% (pulse oximeter/arterial) at the planned time of device placement (uncorrected by oxygen supplementation or intubation).
  • Sustained VT (at the time of the enrollment).
  • Significant right heart failure/right ventricular dysfunction.
  • Awake patient who is unable to remain in a stable recumbent position due to restlessness or lack of cooperation for other reasons.
  • Hypertrophic obstructive cardiomyopathy.
  • Left ventricular thrombus.
  • Subjects with a placed IABP.
  • Mitral and/or aortic valve prothesis, or more than mild native mitral or aortic valve stenosis.
  • Aortic valve insufficiency ≥ 2+ (on a 4-grade scale).
  • Mechanical complication of myocardial infarction (e.g., ventricular septal rupture, papillary muscle rupture) or evidence of uncorrected Ventricular Septal Defect or Atrial Septal Defect (VSD/ASD).
  • Brain damage (e.g., anoxic) or suspected brain damage.
  • Stroke or within the past 3 months.
  • Uncorrectable abnormal coagulation parameters (defined as count \< 100,000 or > 2.0 or fibrinogen \< 1.5 g/L) or active uncontrolled bleeding.
  • Allergy, sensitivity or intolerance to heparin, aspirin, Adenosine Diphosphate (ADP) receptor blockers, or contrast media, including known heparin-induced thrombocytopenia.
  • Known allergy, sensitivity or intolerance to nickel.
  • Known or suspected severe lung disease.
  • Evidence of any vascular disease that would preclude placement of the device (e.g., severely calcified and stenosed ilio-femoral vessels).
  • Aortic pathology, such as aortic aneurysms, extreme tortuosity, or calcifications that could pose an undue additional risk to the placement of a pLVAD device.
  • Any known or suspected disorder causing fragility of blood cells or hemolysis.
  • Subject participation in another drug or device trial (post-market registries may be approved by Magenta Medical).
  • \< 1 year due to comorbidities.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Cardiogenic shock

    Acute myocardial infarction or acutely decompensated heart failure and cardiogenic shock patients

    Device: Elevate™ System

Interventions

  • DeviceElevate™ System

    The Elevate™ percutaneous Left Ventricular Assist Device System

06

What researchers measure

Primary outcomes

  1. Initial Safety

    The rate of the composite of Major Device-Related Adverse Events

    Time frame: From device delivery through device removal

  2. Device Effectiveness

    Hemodynamic stability and/or improvement from baseline following device activation, defined as: * Number (percentage) of patients with MAP\>60mmHg * Improvement in MAP

    Time frame: From baseline to 30 minutes of device activation

  3. Device Performance

    * Rate of successful delivery of the Elevate™ System * Rate of successful deployment of the Elevate™ System * Rate of successful use of the Elevate™ System * Rate of successful retrieval of the Elevate™ System

    Time frame: From device delivery through device removal

07

Study locations

8 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jan 2028, 26 months after the start.

Of 52 interventional studies with no phase under Shock, Cardiogenic, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 26 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Dec 19, 2025
StartActual
Nov 5, 2025
Primary completionEst.
Jan 30, 2028
CompletionEst.
Feb 28, 2028
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07293923
Lead sponsor
Magenta Medical Ltd.
Responsible party
Sponsor
First posted
Dec 19, 2025
Start date
Nov 5, 2025
Primary completion
Jan 30, 2028 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
Jul 16, 2026

Study contacts

Yelena Lalazar Sr. Director Clinical Affairs
Contact
yelenal@magentamed.com
+972.50.6829528
Yelena Lalazar
study director · Magenta Medical

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion